Robert Dreicer, MD

Robert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.

A prostate cancer expert explains the potential advantages of sabizabulin, a new treatment for metastatic castration-resistant prostate cancer currently in a phase III clinical trial.

Robert Dreicer, MD, discusses the available second-line therapy options and unmet needs in metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, provides an overview of the first-line therapy options available in metastatic castration-resistant prostate cancer and the recent advances in detection, diagnosis, and treatment.